Physician profile
Amgad Botros
NPI 1679739551
$3,588.95
in general payments reported to CMS, 2019-2025
16 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $714 · 2021: $1,017 · 2022: $79.81 · 2023: $274 · 2024: $335 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,169.80 | 2019-2021 | |
| Boston Scientific Corporation | $808.94 | 2019-2025 | Watchman Access System, Watchman Flx, Avvigo Guidance System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $570.59 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $385.17 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $179.30 | 2021-2024 | Camzyos |
| Astellas Pharma US INC | $112.14 | 2019 | |
| Lantheus Medical Imaging, INC. | $66.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $54.15 | 2024 | |
| Merck Sharp & Dohme LLC | $51.42 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $45.96 | 2021-2023 | Xarelto |
| Irhythm Technologies, INC. | $38.94 | 2019-2020 | |
| Amgen INC. | $29.12 | 2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $25.00 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.01 | 2022 | |
| Medtronic, INC. | $18.26 | 2025 | In.Pact Admiral |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amgad Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.